NASDAQ:REPL Replimune Group Q2 2025 Earnings Report $15.04 0.00 (0.00%) As of 09/4/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Replimune Group EPS ResultsActual EPS-$0.68Consensus EPS -$0.75Beat/MissBeat by +$0.07One Year Ago EPSN/AReplimune Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AReplimune Group Announcement DetailsQuarterQ2 2025Date11/12/2024TimeBefore Market OpensConference Call DateTuesday, November 12, 2024Conference Call Time7:00AM ETUpcoming EarningsReplimune Group's Q2 2027 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Replimune Group Earnings HeadlinesREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS LawSeptember 4 at 10:05 AM | globenewswire.comReplimune Group (NASDAQ:REPL) Sets New 1-Year High - Here's WhySeptember 4 at 4:01 AM | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 7 at 1:00 AM | Profits Run (Ad)Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor HarmSeptember 3, 2026 | globenewswire.comDeadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitSeptember 3, 2026 | globenewswire.comREPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action DeadlineSeptember 3, 2026 | prnewswire.comSee More Replimune Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email. Email Address About Replimune GroupReplimune Group (NASDAQ:REPL) is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses. Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation. The company’s pipeline also includes RP2, RP3 and RP4, each engineered with distinct cytokine or co‐stimulatory transgenes to address different tumor types and immune environments. Clinical studies to date have evaluated these candidates as monotherapies and in combination with checkpoint inhibitors, with initial data reported in melanoma, cutaneous squamous cell carcinoma and other solid tumors. Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune designs and executes clinical trials across North America and Europe. The company’s research and manufacturing infrastructure supports rapid development and scalable production of its viral immunotherapies. Replimune maintains collaborations with academic institutions and clinical research organizations to advance its programs through late-stage studies. Replimune is led by an experienced management team and board of directors with deep expertise in oncology drug development, virology and regulatory affairs. The company’s leadership draws on years of precedent in advancing innovative cancer treatments from early discovery into pivotal clinical trials.View Replimune Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/31 - 09/04Palo Alto vs. Zscaler: Which Cybersecurity Stock Looks Stronger After Earnings?Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key SignalLululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story3 Stocks With September Catalysts Investors Shouldn’t IgnoreParsons’ Pullback May Give Defense and Infrastructure Investors a Second LookPetco Is Still Being Priced Like the Old Petco Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
